GSK wins new reprieve as Hikma's generic Advair delayed again

GSK wins new reprieve as Hikma's generic Advair delayed again(Reuters) - GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura , said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.




from Yahoo News - Latest News & Headlines http://ift.tt/2FMvd6G